# Oryon Cell Therapies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oryon-cell-therapies

- Industry: Biotechnology
- Headquarters: Belmont, US
- Website: www.oryoncelltherapies.com
- Total disclosed funding: $21M
- Latest round: Series A (Mar 23, 2026)
- Investors on record: 1

## About

Oryon Cell Therapies, based in Belmont, US, focuses on advanced regenerative medicine, offering innovative cell therapy solutions aimed at improving healing and recovery processes for various medical conditions.Founded in 2020, Oryon Cell Therapies specializes in developing cell therapy solutions to address significant medical challenges. The company has secured USD 21.00 mn in Series A funding, raised on March 23, 2026, from investors including Byers Capital and Neuro.VC. Oryon has completed one deal to date and operates from its headquarters in Belmont, US.Oryon Cell Therapies specializes in advanced regenerative medicine, focusing on cell therapy solutions designed for a range of medical conditions. Their innovative treatments enhance healing and recovery by utilizing cellular regeneration principles. Targeting chronic diseases, their therapies aim to improve patient outcomes by leveraging the body's natural healing capabilities. Oryon serves healthcare providers, hospitals, and specialized clinics across North America and Europe, aligning its product development with current healthcare demands.Oryon Cell Therapies generates revenue through partnerships with healthcare institutions and direct sales to clinics for advanced therapies. Transactions typically involve service agreements that detail the treatment costs, based on care complexity and duration. These arrangements are tailored for flexibility, facilitating the integration of Oryon’s therapies into existing treatment protocols, thereby ensuring consistent demand for their services.In March 2026, Oryon Cell Therapies raised USD 21.00 mn in Series A funding, which will be allocated to conducting clinical studies and research on neuron replacement therapies for Parkinson’s disease. The company plans to progress its treatments toward regulatory approval while expanding into new markets, specifically targeting Europe and North America by 2027.

## Funding rounds

- Series A, Mar 23, 2026, $21M — Byers Capital

## Investors

- Byers Capital (https://capitalatlas.ai/funds/byers-capital) — Series A